I mean they could go alone, but it’s incredibly risky. The PRV would likely go for 80-100M USD which would cover their P2B EMA + Dual FDA preclin/clin trials, but likely would dry up and not cover the later phase 2 trials for the FDA. I doubt ANP management want to try and tackle these pipelines by themselves, but I could be wrong.0
Chart, page-4320
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
-0.001(1.37%) |
Mkt cap ! $64.91M | |||
| Open | High | Low | Value | Volume |
| 7.4¢ | 7.5¢ | 7.2¢ | $66.67K | 916.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 127509 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.4¢ | 97444 | 1 |
View Market Depth
| Last trade - 15.23pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
-0.001 ( 2.70 %) |
||||
| Open | High | Low | Volume | ||
| 7.3¢ | 7.3¢ | 7.2¢ | 1650 | ||
| Last updated 13.54pm 24/05/2024 ? | |||||
| PER (ASX) Chart |